Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
100 participants
INTERVENTIONAL
2015-01-31
2017-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C
NCT00298714
Prevention of Decompensation in Liver Cirrhosis
NCT00239096
Lanreotide as Treatment of Polycystic Livers
NCT00565097
A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease
NCT01277094
Anti-Fibrotic Effects of Losartan In Nash Evaluation Study
NCT01051219
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients received the oral losartan
50 patients with obstructive jaundice indicated for ERCP and received oral losartan 1 hour before ERCP as a prophylaxis of post-ERCP pancreatitis
oral losatan
50 mg of oral losartan one hour before the ERCP once
patients didn't receive the oral losartan
50 patients with obstructive jaundice indicated for ERCP and didn't receive any prophylactic drugs
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
oral losatan
50 mg of oral losartan one hour before the ERCP once
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with obstructive jaundice.
* Patients with dilated intra-hepatic or extra-hepatic bile ducts due to malignant or benign lesions.
Exclusion Criteria
* Patients with clinically evident acute pancreatitis before the procedure
* Patients with previous endoscopic or surgical sphincterotomy
* Patients with current use of losartan
* Patients who are allergic or hypersensitive to losartan or hydro soluble contrast solutions
* Patients receiving NSAIDS within a week prior to assessment
* Patients with severe co-morbid conditions as cardiovascular disease, renal failure or decompensated liver cirrhosis.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shereen Abou Bakr Saleh
Assistant Professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
689
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.